Skip to main content

Table 2 Selected feature set

From: Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection

No.

encoding*

metabolite ratio

No.

encoding

metabolite ratio

1

arctan (1/7)*

M-1/ncm5U

23

arctan (20/3)

X/ψ

2

arctan (1/12)

M-1/m1A

24

arctan (20/35)

X/ms2t6A

3

arctan (2/21)

DHU/SAH

25

arctan (21/30)

SAH/m2 2G

4

arctan (3/18)

Ψ/m3U

26

arctan (22/30)

m1I/m2 2G

5

arctan (5/7)

C/ncm5U

27

arctan (23/18)

m1G/m3U

6

arctan (5/11)

C/AICA riboside

28

arctan (25/5)

ac4C/C

7

arctan (6/18)

acp3U/m3U

29

arctan (25/10)

ac4C/m3C

8

arctan (6/19)

acp3U/N6-SAR

30

arctan (25/22)

ac4C/m1I

9

arctan (8/23)

M-3/m1G

31

arctan (26/28)

m2G/ms2io6A

10

arctan (9/21)

U/SAH

32

arctan (26/30)

m2G/m2 2G

11

arctan (11/5)

AICA riboside/C

33

arctan (27/13)

M-4/2,5-PCNR

12

arctan (11/33)

AICA riboside/MTA

34

arctan (28/19)

ms2io6A/N6-SAR

13

arctan (12/10)

m1A/m3C

35

arctan (29/34)

m2,2,7G/m6t6A

14

arctan (12/18)

m1A/m3U

36

arctan (29/35)

m2,2,7G/ms2t6A

15

arctan (13/9)

2,5-PCNR/U

37

arctan (30/21)

m2 2G/SAH

16

arctan (13/20)

2,5-PCNR/X

38

arctan (31/2)

mcm5s2U/DHU

17

arctan (14/21)

m7G/SAH

39

arctan (31/24)

mcm5s2U/293

18

arctan (14/26)

m7G/m2G

40

arctan (33/11)

MTA/AICA riboside

19

arctan (16/22)

3,4-PCNR/m1I

41

arctan (33/17)

MTA/m6 1A

20

arctan (18/10)

m3U/m3C

42

arctan (33/34)

MTA/m6t6A

21

arctan (18/21)

m3U/SAH

43

arctan (34/12)

m6t6A/m1A

22

arctan (19/30)

N6-SAR/m2 2G

44

arctan (34/19)

m6t6A/N6-SAR

  1. Feature set for best classification performance.
  2. *Numbering of arctan encoding combinations consistent with table 1. For metabolite abbreviations, please refer to Table 1.